ReNewVax
Liverpool
About ReNewVax
ReNewVax develops pneumococcal vaccines to prevent life-threatening bacterial infections and diseases such as pneumonia, meningitis, and sepsis. Its product pipeline includes RVX-001, a novel and cost-effective protein-based vaccine against pneumococcal invasive disease, RVX-002 Streptococcus pyogenes vaccine for invasive neonatal disease, and RVX-003 Streptococcus vaccine for toxic shock syndrome.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $326.3K
- Funding stage: Seed
- Last round: Pre-Seed (Oct 2024)
- Website: renewvax.com
- Phone: 0203 488 0710
Industries & Categories
Biotechnology, Health Care, Life Science, Medical
Social Profiles
Canonical: https://fsome.com/organization/renewvax-74455 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.